Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Crown

Showing results (81-90 of 102) with videos related to

Pageof 11
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2008
ADAM-17 predicts adverse outcome in patients with breast cancerP M McGowan, E McKiernan, F Bolster, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2000
A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancerA Di Leo, J Crown, J M Nogaret, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 2, 2011
Src: a potential target for the treatment of triple-negative breast cancerD Tryfonopoulos, S Walsh, D M Collins, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 13, 2012
ADAM-17: a novel therapeutic target for triple negative breast cancerP M McGowan, M Mullooly, F Caiazza, et al.
Breast Cancer Research and Treatment|April 11, 2016
Late cardiac effects of chemotherapy in breast cancer survivors treated with adjuvant doxorubicin: 10-year follow-upG Murtagh, T Lyons, E O'Connell, et al.
Cancer Chemotherapy and Pharmacology|April 28, 2006
A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancerR O'Connor, M O'Leary, J Ballot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2006
Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1B M Ryan, G E Konecny, S Kahlert, et al.
Seminars in Oncology|February 1, 1996
Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experienceC Hudis, A Seidman, G Raptis, et al.
British Journal of Cancer|November 13, 2008
Protein kinase Cdelta expression in breast cancer as measured by real-time PCR, western blotting and ELISAE McKiernan, K O'Brien, N Grebenchtchikov, et al.
British Journal of Cancer|March 18, 2010
Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasisN Walsh, S Kennedy, A M Larkin, et al.
Pageof 11

Showing results (81-90 of 102) with videos related to

Sort By:
Pageof 11
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2008
ADAM-17 predicts adverse outcome in patients with breast cancerP M McGowan, E McKiernan, F Bolster, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2000
A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancerA Di Leo, J Crown, J M Nogaret, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 2, 2011
Src: a potential target for the treatment of triple-negative breast cancerD Tryfonopoulos, S Walsh, D M Collins, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 13, 2012
ADAM-17: a novel therapeutic target for triple negative breast cancerP M McGowan, M Mullooly, F Caiazza, et al.
Breast Cancer Research and Treatment|April 11, 2016
Late cardiac effects of chemotherapy in breast cancer survivors treated with adjuvant doxorubicin: 10-year follow-upG Murtagh, T Lyons, E O'Connell, et al.
Cancer Chemotherapy and Pharmacology|April 28, 2006
A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancerR O'Connor, M O'Leary, J Ballot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2006
Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1B M Ryan, G E Konecny, S Kahlert, et al.
Seminars in Oncology|February 1, 1996
Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experienceC Hudis, A Seidman, G Raptis, et al.
British Journal of Cancer|November 13, 2008
Protein kinase Cdelta expression in breast cancer as measured by real-time PCR, western blotting and ELISAE McKiernan, K O'Brien, N Grebenchtchikov, et al.
British Journal of Cancer|March 18, 2010
Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasisN Walsh, S Kennedy, A M Larkin, et al.
Pageof 11